**SUPPLEMENTARY TABLES**

Supplementary Table 1. Clinicopathological characteristics of ESCC patient samples (n=32).

| Characteristics          | No. of cases (%) |
|--------------------------|------------------|
| **Age (y)**              |                  |
| <65                      | 15 (46.9)        |
| ≥65                      | 17 (53.1)        |
| **Gender**               |                  |
| Male                     | 28 (87.5)        |
| Female                   | 4 (12.5)         |
| **TNM stage**            |                  |
| I                        | 6 (18.8)         |
| II                       | 13 (40.6)        |
| III                      | 13 (40.6)        |
| **T classification**     |                  |
| T1                       | 5 (15.6)         |
| T2                       | 9 (28.1)         |
| T3                       | 18 (56.3)        |
| T4                       | 0 (0)            |
| **N classification**     |                  |
| N0                       | 12 (37.5)        |
| N1                       | 17 (53.1)        |
| N2-NX                    | 3 (9.4)          |
| **Metastasis**           |                  |
| No                       | 32 (100)         |
| Yes                      | 0 (0)            |
| **Vascular invasion**    |                  |
| No                       | 25 (78.1)        |
| Yes                      | 7 (21.9)         |
| **Lymphatic invasion**   |                  |
| No                       | 13 (40.6)        |
| Yes                      | 19 (59.4)        |
| **Expression of miR-221**|                  |
| Low expression           | 16 (50)          |
| High expression          | 16 (50)          |
Supplementary Table 2. Correlation between miR-196a-5p expression and clinicopathologic characteristics of ESCC patients (n=32).

| Characteristics       | miR-196a-5p | p value |
|------------------------|-------------|---------|
|                        | Low expression, no. cases | High expression, no. cases |
| Age(y)                 |              |         |
| <65                    | 7            | 8       | 0.723   |
| ≥65                    | 9            | 8       |
| Gender                 |              |         |
| Male                   | 15           | 13      | 0.285   |
| Female                 | 1            | 3       |
| TNM stage              |              |         |
| I                      | 2            | 4       |         |
| II                     | 8            | 5       | 0.488   |
| III                    | 6            | 7       |
| T classification       |              |         |
| T1                     | 5            | 0       |         |
| T2                     | 2            | 7       | 0.020   |
| T3                     | 9            | 9       |
| T4                     | 0            | 0       |
| N classification       |              |         |
| N0                     | 7            | 5       |         |
| N1                     | 8            | 9       | 0.696   |
| N2-NX                  | 1            | 2       |
| Metastasis             |              |         |
| No                     | 20           | 12      |         |
| Yes                    | 0            | 0       |         |
| Vascular invasion      |              |         |
| No                     | 14           | 11      | 0.200   |
| Yes                    | 2            | 5       |
| Lymphatic invasion     |              |         |
| No                     | 7            | 6       | 0.719   |
| Yes                    | 9            | 10      |         |
Supplementary Table 3. Correlation between miR-1-3p expression and clinicopathologic characteristics of ESCC patients (n=32).

| Characteristics | miR-1-3p |          |          | p value |
|----------------|----------|----------|----------|---------|
|                |          | Low expression, no. cases | High expression, no. cases |         |
| Age(y)         |          | 9        | 6        | 0.288   |
| <65            |          | 9        | 6        |         |
| ≥65            |          | 7        | 10       |         |
| Gender         |          |          |          | 0.285   |
| Male           |          | 15       | 13       |         |
| Female         |          | 1        | 3        |         |
| TNM stage      |          |          |          | 0.663   |
| I              |          | 2        | 4        |         |
| II             |          | 7        | 6        |         |
| III            |          | 7        | 6        |         |
| T classification|         |          |          | 0.020   |
| T1             |          | 9        | 9        |         |
| T2             |          | 2        | 7        |         |
| T3             |          | 5        | 0        |         |
| T4             |          | 0        | 0        |         |
| N classification|         |          |          | 0.822   |
| N0             |          | 6        | 6        |         |
| N1             |          | 8        | 9        |         |
| N2-NX          |          | 2        | 1        |         |
| Metastasis     |          |          |          |         |
| No             |          | 16       | 16       |         |
| Yes            |          | 0        | 0        |         |
| Vascular invasion|        |          |          | 0.200   |
| No             |          | 14       | 11       |         |
| Yes            |          | 2        | 5        |         |
| Lymphatic invasion|      |          |          | 0.719   |
| No             |          | 6        | 7        |         |
| Yes            |          | 10       | 9        |         |